作者:Davie Cappoen、Jure Vajs、Cynthia Uythethofken、Andrej Virag、Vanessa Mathys、Marijan Kočevar、Luc Verschaeve、Martin Gazvoda、Slovenko Polanc、Kris Huygen、Janez Košmrlj
DOI:10.1016/j.ejmech.2014.02.065
日期:2014.4
novel compounds for therapeutic use. Identification and study of compounds with the ability to inhibit Mycobacterium tuberculosis is of paramount importance. For this reason, a library of substituted 1,3-diaryltriazenes based on the acting component of the anti-trypanosomal drug, diminazene aceturate was created and evaluated for its potential as anti-tubercular agent. Several compounds were identified
耐药性结核病的快速产生和传播导致对用于治疗用途的新型化合物的持续需求。鉴定和研究具有抑制结核分枝杆菌能力的化合物至关重要。因此,建立了基于抗锥虫药物地那米嗪乙酸酯的作用成分的取代的1,3-二芳基三氮烯文库,并对其作为抗结核药的潜力进行了评估。鉴定出对结核分枝杆菌和其他临床相关分枝杆菌物种(如牛分枝杆菌,鸟分枝杆菌和溃疡分枝杆菌)具有亚微摩尔抑制浓度的几种化合物。。尽管化合物的文库显示出相当大的急性细胞毒性,但未观察到遗传毒性。最后,选择具有最佳生物学特性的三氮烯14(IC 50 = 3.26μM,NI 50 = 24.22μM,SI = 7.44)。化合物14显示出抑制细胞内复制和耐多药结核分枝杆菌生长的能力。结果表明该分子是进一步研究和优化的有趣支架。